CV Sciences, Inc. has released its financial results for the second quarter ending June 30, 2026, reporting significant challenges in revenue generation alongside operational cost reductions.
The company generated $3.0 million in revenue for Q2 2026, which represents a 17.5% decrease from $3.6 million in the same period of 2025. Compared to the previous quarter, revenue decreased slightly from $3.2 million. This revenue drop has been attributed primarily to regulatory restrictions impacting sales volumes at both federal and state levels.
Despite the decline in revenue, CV Sciences successfully reduced its operating expenses by 11.3%, bringing them down to $1.7 million in Q2 2026 from $2.0 million in the same quarter of 2025. This reduction was also a 6.9% decrease from $1.9 million in Q1 2026, indicating a continued effort to manage costs effectively.
The company reported an adjusted EBITDA loss of $0.1 million in Q2 2026, contrasting with a positive adjusted EBITDA of $0.1 million in the same quarter of the previous year. This shift reflects persistent financial challenges as the firm navigates a shifting market landscape. The gross margin for the quarter was recorded at 48.6%, down from 50.9% in Q2 2025.
As of the end of Q2 2026, CV Sciences reported a cash balance of $0.3 million. The CEO, Joseph Dowling, indicated that the company is focused on improving profitability and generating positive cash flow as market conditions stabilize. In addition, the company has expanded its +PlusHLTH™ product line to enhance its offerings in personalized wellness solutions.
In a significant regulatory update, the U.S. Senate approved Continuing Resolution H.R. 6500, which delays the implementation of stringent regulations on hemp-derived cannabinoid products. This development offers the company additional time to work on a more sustainable regulatory framework.
CV Sciences, Inc. reported revenues of $3.0 million for the second quarter of 2026. This reflects a decrease from $3.6 million in the same quarter of 2025 and a slight increase from $3.2 million in the first quarter of 2026.
Operating expenses were reduced by 11.3% to $1.7 million in the second quarter of 2026 compared to $2.0 million in the same quarter of 2025, and decreased by 6.9% from $1.9 million in the first quarter of 2026.
CV Sciences reported an adjusted EBITDA loss of $0.1 million in the second quarter of 2026, compared to a positive adjusted EBITDA of $0.1 million in the second quarter of 2025 and a similar adjusted EBITDA loss of $0.1 million in the first quarter of 2026.
The decline in sales for CV Sciences, which fell by 17.5% in the second quarter of 2026, was primarily driven by lower sales volume attributed to restrictive regulations at the federal level and in certain states.
As of the end of the second quarter of 2026, CV Sciences reported a cash balance of $0.3 million. This represents a decrease compared to previous periods.
CV Sciences reported an operating loss of $0.3 million for the second quarter of 2026, compared to an operating loss of $0.1 million in the second quarter of 2025.
CV Sciences noted that the U.S. Senate voted 61-32 to approve Continuing Resolution H.R. 6500, which delays the implementation of restrictive provisions for hemp-derived cannabinoid products, potentially allowing more time to develop a long-term regulatory solution.
CV Sciences focuses on consumer wellness products, primarily through its +PlusCBD™ and +PlusHLTH™ brands, offering hemp extracts and non-cannabinoid supplements, as well as plant-based food products under the Cultured Foods™ brand.